HIF-1α inhibition is a promising strategy for the treatment of various tumor types, including CRC, which is based on the delay in angiogenesis and the decrease in cell viability under the conditions of hypoxia and inflammation [46,47,48]. This evidence concerns the gene HIF1A and neoplasm.